<DOC>
	<DOCNO>NCT02551874</DOCNO>
	<brief_summary>This research study subject inadequately control type 2 diabetes mellitus ( T2DM ) compare glycemic control ( measure HbA1c ) subject co-administered saxagliptin dapagliflozin , addition metformin without sulfonylurea , subject receive insulin glargine , addition metformin without sulfonylurea , treatment period 52 week .</brief_summary>
	<brief_title>A 24-week Open-Label , Phase 3b Trial With 28-week Extension Evaluate Efficacy Safety Saxagliptin Co-administered With Dapagliflozin Compared Insulin Glargine Subjects withType 2 Diabetes Who Have Glycemic Control Metformin</brief_title>
	<detailed_description>CV181-369 ; A 24 Week International , Open-Label Trial With 28 Week Extension Evaluate Efficacy Saxagliptin Co-administered With Dapagliflozin Compared Insulin Glargine Subjects With Type 2 Diabetes Metformin With Without Sulfonylurea Therapy</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com At least 18 year age screen HbA1c ≥ 8 % ≤ 12 % screen Fasting plasma glucose ( FPG ) ≤ 270 mg/dL ( 15mmol/L ) Stable dose metformin ≥ 1500 mg per day without stable dose sulfonylurea ( define least 50 % maximal dose per local label ) least 8 week estimate glomerular filtration rate ( eGFR ) &amp; lt ; 60 ml/ml/1.73m2 Body Mass Index ≤ 45.0 kg/m2 Clinical diagnosis Type 1 diabetes History ketoacidosis Renal , hepatic pancreatic disease Impairment renal function ( defined creatinine clearance [ CrCl ] &lt; 60 mL/min Cardiovascular vascular disease identify within 3 month participationImpairment renal function ( defined creatinine clearance [ CrCl ] &lt; 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>